$ 2023 Q1 10-Q

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001058330
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	roag	Accounts Receivable AccountsReceivable		usd
CY2020Q4	us-gaap	Inventory Net InventoryNet		usd
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2020Q4	roag	Fully Controlled Companies FullyControlledCompanies		usd
CY2020Q4	roag	Associated Companies AssociatedCompanies		usd
CY2020Q4	roag	Shares Publicly Traded Srsg SharesPubliclyTradedSrsg		usd
CY2020Q4	roag	Property Plant And Equipment PropertyPlantAndEquipment		usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2020Q4	us-gaap	Goodwill Goodwill		usd
CY2020Q4	roag	Assets Pledged AssetsPledged		usd
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent		usd
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent		usd
CY2020Q4	roag	Related Party Loans RelatedPartyLoans		usd
CY2020Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent		usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2020Q4	roag	Sba Loan SbaLoan		usd
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2021Q3	roag	Preferred Stock Series D0.00001 Par Value.1 Share Authorized1 And Zero Shares Issued And Outstanding As Of December312018 And2017 Respectively1 PreferredStockSeriesD0.00001ParValue.1ShareAuthorized1AndZeroSharesIssuedAndOutstandingAsOfDecember312018And2017Respectively1		usd
CY2020Q4	roag	Preferred Stock Series D0.00001 Par Value.1 Share Authorized1 And Zero Shares Issued And Outstanding As Of December312018 And2017 Respectively1 PreferredStockSeriesD0.00001ParValue.1ShareAuthorized1AndZeroSharesIssuedAndOutstandingAsOfDecember312018And2017Respectively1		usd
CY2021Q3	roag	Preferred Stock Series E0.00001 Par Value.12 Shares Authorized12 And Zero Shares Issued And Outstanding As Of December312019 And2018 Respectively PreferredStockSeriesE0.00001ParValue.12SharesAuthorized12AndZeroSharesIssuedAndOutstandingAsOfDecember312019And2018Respectively		usd
CY2020Q4	roag	Preferred Stock Series E0.00001 Par Value.12 Shares Authorized12 And Zero Shares Issued And Outstanding As Of December312019 And2018 Respectively PreferredStockSeriesE0.00001ParValue.12SharesAuthorized12AndZeroSharesIssuedAndOutstandingAsOfDecember312019And2018Respectively		usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2020Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2020Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2020Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2021Q3	roag	Board Member Fees BoardMemberFees		usd
	roag	Board Member Fees BoardMemberFees		usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees		usd
	us-gaap	Professional Fees ProfessionalFees		usd
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
CY2021Q3	roag	Derivative Liability Expense DerivativeLiabilityExpense		usd
	roag	Derivative Liability Expense DerivativeLiabilityExpense		usd
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2021Q3	roag	Tequila Armero S.A De C.V TequilaArmeroS.aDeC.v		usd
CY2020Q3	roag	Tequila Armero S.A De C.V TequilaArmeroS.aDeC.v		usd
	roag	Tequila Armero S.A De C.V TequilaArmeroS.aDeC.v		usd
CY2020Q3	roag	Industrias Naturales De Tequilas S.A De C.V IndustriasNaturalesDeTequilasS.aDeC.v		usd
	roag	Industrias Naturales De Tequilas S.A De C.V IndustriasNaturalesDeTequilasS.aDeC.v		usd
CY2020Q3	roag	Tequila Copter S.A.De C.V TequilaCopterS.a.DeC.v		usd
	roag	Tequila Copter S.A.De C.V TequilaCopterS.a.DeC.v		usd
CY2020Q3	roag	Sobre Todo Alimentacion S.A.De C.V SobreTodoAlimentacionS.a.DeC.v		usd
	roag	Sobre Todo Alimentacion S.A.De C.V SobreTodoAlimentacionS.a.DeC.v		usd
CY2020Q3	roag	Turasu Spr De Rl TurasuSprDeRl		usd
	roag	Turasu Spr De Rl TurasuSprDeRl		usd
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2020Q2	roag	Conversion Of Series D Preferred Stock For Common Stock ConversionOfSeriesDPreferredStockForCommonStock		usd
CY2021Q1	roag	Return Of Common Stock Issued In Connection With Acquisition Of Business ReturnOfCommonStockIssuedInConnectionWithAcquisitionOfBusiness		usd
CY2021Q1	roag	Conversion Of Series E Preferred Stock For Common Stock ConversionOfSeriesEPreferredStockForCommonStock		usd
CY2021Q3	roag	Not Issued Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings NotIssuedSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferings		usd
CY2021Q3	roag	Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue		usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization		usd
	roag	Common Stock Issued In Exchange For Fees And Services CommonStockIssuedInExchangeForFeesAndServices		usd
	roag	Preferred Stock Issued As Compensation To Employees Officers Andor Directors PreferredStockIssuedAsCompensationToEmployeesOfficersAndorDirectors		usd
	roag	Preferred Stock Issued In Exchange For Fees And Services PreferredStockIssuedInExchangeForFeesAndServices		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	roag	Increase Decrease In Other Investments Associated Companies IncreaseDecreaseInOtherInvestmentsAssociatedCompanies		usd
	roag	Increase Decrease In Other Investments Associated Companies IncreaseDecreaseInOtherInvestmentsAssociatedCompanies		usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
	roag	Assets Impairement AssetsImpairement		usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	roag	Increase Decrease In Related Party Loans IncreaseDecreaseInRelatedPartyLoans		usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities		usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
	roag	Increase Decrease In Contingencias And Commitments IncreaseDecreaseInContingenciasAndCommitments		usd
	roag	Cash Received From Merger Transaction CashReceivedFromMergerTransaction		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	roag	Proceeds From Short Term Loans ProceedsFromShortTermLoans		usd
	roag	Related Party Loan RelatedPartyLoan		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Interest Paid InterestPaid		usd
	us-gaap	Interest Paid InterestPaid		usd
	roag	Common Stock Issued To Reduce Convertible Promissory Notes Payable CommonStockIssuedToReduceConvertiblePromissoryNotesPayable		usd
	roag	Series E Preferred Stock Issued In Lieu Of Cash For Accrued Officer Compensation SeriesEPreferredStockIssuedInLieuOfCashForAccruedOfficerCompensation		usd
	roag	Common Stock Issued In Connection With Acquisition Of Business CommonStockIssuedInConnectionWithAcquisitionOfBusiness		usd
	roag	Preferred Stock Issued In Connection With Acquisition Of Business PreferredStockIssuedInConnectionWithAcquisitionOfBusiness		usd
	roag	Conversion Of Related Party Debt ConversionOfRelatedPartyDebt		usd
	roag	Conversion Of Related Party Debt ConversionOfRelatedPartyDebt		usd
	roag	Capital Lease Additions To Fixed Assets CapitalLeaseAdditionsToFixedAssets		usd
	roag	Capital Lease Additions To Fixed Assets CapitalLeaseAdditionsToFixedAssets		usd
	roag	Convertible Promissory Notes ConvertiblePromissoryNotes		shares
	roag	Convertible Promissory Notes ConvertiblePromissoryNotes		shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes		usd
	roag	Accrued Expense Benefit AccruedExpenseBenefit		usd
	roag	Accrued Expense Benefit AccruedExpenseBenefit		usd
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability		usd
CY2021Q3	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2020Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings		usd
	roag	Record Non Cash Derivative Liability On Notes RecordNonCashDerivativeLiabilityOnNotes		usd
CY2021Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	00-24723
	dei	Entity Registrant Name EntityRegistrantName	ROGUE ONE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0393257
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1023 K Street, N.W.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 454
	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	DC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2005
	dei	City Area Code CityAreaCode	405
	dei	Local Phone Number LocalPhoneNumber	733-1567
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	312655147	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44342	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111	usd
CY2021Q3	roag	Accounts Receivable AccountsReceivable	826297	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	6996553	usd
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	128080	usd
CY2021Q3	roag	Fully Controlled Companies FullyControlledCompanies	8400	usd
CY2021Q3	roag	Associated Companies AssociatedCompanies	703740	usd
CY2021Q3	roag	Shares Publicly Traded Srsg SharesPubliclyTradedSrsg	7432862	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	16140274	usd
CY2020Q4	us-gaap	Assets Current AssetsCurrent	111	usd
CY2021Q3	roag	Property Plant And Equipment PropertyPlantAndEquipment	314976	usd
CY2021Q3	roag	Loans Loans	50000	usd
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	94411	usd
CY2021Q3	us-gaap	Goodwill Goodwill	10804239	usd
CY2021Q3	roag	Assets Pledged AssetsPledged	246102	usd
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	11509728	usd
CY2021Q3	us-gaap	Assets Assets	27650002	usd
CY2020Q4	us-gaap	Assets Assets	111	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1785337	usd
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	165466	usd
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1678775	usd
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1555862	usd
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	346020	usd
CY2021Q3	roag	Related Party Loans RelatedPartyLoans	351233	usd
CY2021Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	526768	usd
CY2021Q3	roag	Notes Payable Third Party NotesPayableThirdParty	12500	usd
CY2021Q3	roag	Notes Payable Related Party NotesPayableRelatedParty	6055	usd
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	131678082	shares
CY2020Q4	roag	Notes Payable Related Party NotesPayableRelatedParty	4505	usd
CY2021Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1485948	usd
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1559803	usd
CY2021Q3	roag	Convertible Notes Payable Accrued Interest ConvertibleNotesPayableAccruedInterest	743643	usd
CY2021Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2934454	usd
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2298820	usd
CY2021Q3	us-gaap	Bank Overdrafts BankOverdrafts	179	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9870910	usd
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5584456	usd
CY2021Q3	roag	Sba Loan SbaLoan	155972	usd
CY2021Q3	us-gaap	Liabilities Liabilities	10026882	usd
CY2020Q4	us-gaap	Liabilities Liabilities	5584456	usd
CY2021Q3	roag	Common Stock To Be Issued CommonStockToBeIssued	378439	usd
CY2021Q3	roag	Preferred Shares Series E Conversion Rights PreferredSharesSeriesEConversionRights	225000	usd
CY2021Q3	roag	Apic On Shares To Be Issued ApicOnSharesToBeIssued	18843105	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	3408995	usd
CY2021Q3	roag	Preferred Stock Serieis Par Value PreferredStockSerieisParValue	0.00001
CY2020Q4	roag	Preferred Stock Serieis Par Value PreferredStockSerieisParValue	0.00001
CY2021Q3	roag	Preferred Stock Serieis Authorized PreferredStockSerieisAuthorized	69999990	shares
CY2021Q3	roag	Preferred Stock Serieis Issued PreferredStockSerieisIssued	10000000	shares
CY2021Q3	roag	Preferred Stock Serieis Outstanding PreferredStockSerieisOutstanding	10000000	shares
CY2020Q4	roag	Preferred Stock Serieis Issued PreferredStockSerieisIssued	10000000	shares
CY2020Q4	roag	Preferred Stock Serieis Outstanding PreferredStockSerieisOutstanding	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	100	usd
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	usd
CY2021Q3	roag	Preferred Stock Serieis D Par Value PreferredStockSerieisDParValue	0.00001
CY2020Q4	roag	Preferred Stock Serieis D Par Value PreferredStockSerieisDParValue	0.00001
CY2021Q3	roag	Preferred Stock Serieis D Authorized PreferredStockSerieisDAuthorized	1	shares
CY2020Q4	roag	Preferred Stock Serieis D Authorized PreferredStockSerieisDAuthorized	1	shares
CY2021Q3	roag	Preferred Stock Serieis D Issued PreferredStockSerieisDIssued	0	shares
CY2021Q3	roag	Preferred Stock Serieis D Outstanding PreferredStockSerieisDOutstanding	0	shares
CY2020Q4	roag	Preferred Stock Serieis D Issued PreferredStockSerieisDIssued	0	shares
CY2020Q4	roag	Preferred Stock Serieis D Outstanding PreferredStockSerieisDOutstanding	0	shares
CY2021Q3	roag	Preferred Stock Serieis E Par Value PreferredStockSerieisEParValue	0.00001
CY2020Q4	roag	Preferred Stock Serieis E Par Value PreferredStockSerieisEParValue	0.00001
CY2021Q3	roag	Preferred Stock Serieis E Authorized PreferredStockSerieisEAuthorized	50	shares
CY2020Q4	roag	Preferred Stock Serieis E Authorized PreferredStockSerieisEAuthorized	50	shares
CY2021Q3	roag	Preferred Stock Serieis E Issued PreferredStockSerieisEIssued	48	shares
CY2021Q3	roag	Preferred Stock Serieis E Outstanding PreferredStockSerieisEOutstanding	48	shares
CY2020Q4	roag	Preferred Stock Serieis E Outstanding PreferredStockSerieisEOutstanding	20	shares
CY2020Q4	roag	Preferred Stock Serieis E Outstanding PreferredStockSerieisEOutstanding	20	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	131678082	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101925194	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101925194	shares
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10536740	usd
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8984757	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15900941	usd
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14670127	usd
CY2021Q3	roag	Total Stockholders Equity TotalStockholdersEquity	17623120	usd
CY2020Q4	roag	Total Stockholders Equity TotalStockholdersEquity	-5583345	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27650002	usd
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111	usd
CY2021Q3	us-gaap	Revenues Revenues	1198434	usd
	us-gaap	Revenues Revenues	1198434	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1019678	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1019678	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	178755	usd
	us-gaap	Gross Profit GrossProfit	178755	usd
CY2020Q3	roag	Board Member Fees BoardMemberFees	15000	usd
	roag	Board Member Fees BoardMemberFees	45000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	300986	usd
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43678	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	688529	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61429	usd
CY2020Q3	us-gaap	Professional Fees ProfessionalFees	9000	usd
	us-gaap	Professional Fees ProfessionalFees	76935	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16870	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16870	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	317857	usd
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	67678	usd
	us-gaap	Operating Expenses OperatingExpenses	705400	usd
	us-gaap	Operating Expenses OperatingExpenses	183364	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-139101	usd
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-67678	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-526644	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-183364	usd
CY2020Q3	roag	Derivative Liability Expense DerivativeLiabilityExpense	27713	usd
	roag	Derivative Liability Expense DerivativeLiabilityExpense	129961	usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-187035	usd
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-137316	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-635633	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2730012	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	72189	usd
CY2020Q3	us-gaap	Interest Expense InterestExpense	76212	usd
	us-gaap	Interest Expense InterestExpense	212513	usd
	us-gaap	Interest Expense InterestExpense	199153	usd
	roag	Other Income Expenses OtherIncomeExpenses	-4842	usd
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-14418	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-14418	usd
CY2021Q3	roag	Liabilities Writeoff LiabilitiesWriteoff	163236	usd
	roag	Liabilities Writeoff LiabilitiesWriteoff	163236	usd
CY2021Q3	us-gaap	Other Expenses OtherExpenses	110406	usd
CY2020Q3	us-gaap	Other Expenses OtherExpenses	241241	usd
	us-gaap	Other Expenses OtherExpenses	704170	usd
	us-gaap	Other Expenses OtherExpenses	3059126	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-249507	usd
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-308919	usd
	us-gaap	Profit Loss ProfitLoss	-1230814	usd
	us-gaap	Profit Loss ProfitLoss	-3242490	usd
CY2021Q3	roag	Industrias Naturales De Tequilas S.A De C.V IndustriasNaturalesDeTequilasS.aDeC.v	19080	usd
	roag	Industrias Naturales De Tequilas S.A De C.V IndustriasNaturalesDeTequilasS.aDeC.v	19080	usd
CY2021Q3	roag	Tequila Copter S.A.De C.V TequilaCopterS.a.DeC.v	20426	usd
	roag	Tequila Copter S.A.De C.V TequilaCopterS.a.DeC.v	20426	usd
CY2021Q3	roag	Sobre Todo Alimentacion S.A.De C.V SobreTodoAlimentacionS.a.DeC.v	3773	usd
	roag	Sobre Todo Alimentacion S.A.De C.V SobreTodoAlimentacionS.a.DeC.v	3773	usd
CY2021Q3	roag	Turasu Spr De Rl TurasuSprDeRl	18706	usd
	roag	Turasu Spr De Rl TurasuSprDeRl	18706	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	61985	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	61985	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-187523	usd
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-308919	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1168829	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3242490	usd
CY2021Q3	roag	Net Income Loss Per Share Applicable To Common Stockholders Basic NetIncomeLossPerShareApplicableToCommonStockholdersBasic	-0.00
CY2020Q3	roag	Net Income Loss Per Share Applicable To Common Stockholders Basic NetIncomeLossPerShareApplicableToCommonStockholdersBasic	-0.00
	roag	Net Income Loss Per Share Applicable To Common Stockholders Basic NetIncomeLossPerShareApplicableToCommonStockholdersBasic	-0.01
	roag	Net Income Loss Per Share Applicable To Common Stockholders Basic NetIncomeLossPerShareApplicableToCommonStockholdersBasic	-0.03
CY2021Q3	roag	Net Income Loss Per Share Applicable To Common Stockholders Diluted NetIncomeLossPerShareApplicableToCommonStockholdersDiluted	-0.00
CY2020Q3	roag	Net Income Loss Per Share Applicable To Common Stockholders Diluted NetIncomeLossPerShareApplicableToCommonStockholdersDiluted	-0.00
	roag	Net Income Loss Per Share Applicable To Common Stockholders Diluted NetIncomeLossPerShareApplicableToCommonStockholdersDiluted	-0.01
	roag	Net Income Loss Per Share Applicable To Common Stockholders Diluted NetIncomeLossPerShareApplicableToCommonStockholdersDiluted	-0.03
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115739401	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97081861	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115739401	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97081861	shares
CY2021Q3	roag	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	115739401	shares
CY2020Q3	roag	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	97081861	shares
	roag	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	115739401	shares
	roag	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	97081861	shares
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5140453	usd
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916070	usd
CY2020Q2	roag	Issuance Of Series E Preferred Stock To Officer As Compensation IssuanceOfSeriesEPreferredStockToOfficerAsCompensation	17500	usd
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8039023	usd
CY2020Q3	roag	Issuance Of Series E Preferred Stock In Exchange For Fees And Services Rendered IssuanceOfSeriesEPreferredStockInExchangeForFeesAndServicesRendered	40000	usd
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-308919	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8307941	usd
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	2676269	usd
CY2020Q4	roag	Issuance Of Series E Preferred Stock To Officer As Compensation IssuanceOfSeriesEPreferredStockToOfficerAsCompensation	48328	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5583344	usd
CY2021Q1	roag	Issuance Of Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings Value IssuanceOfSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue	40000	usd
CY2021Q1	roag	Issuance Of Series E Preferred And Common Stock As Compensation To Employees Officers Andor Director IssuanceOfSeriesEPreferredAndCommonStockAsCompensationToEmployeesOfficersAndorDirector	90000	usd
CY2021Q1	roag	Issuance Of Series E Preferred And Common Stock As Compensation To Employees Officers Andor Directors IssuanceOfSeriesEPreferredAndCommonStockAsCompensationToEmployeesOfficersAndorDirectors	225000	usd
CY2021Q1	roag	Issuance Of Series E Preferred Stock In Exchange For Fees And Services Rendered IssuanceOfSeriesEPreferredStockInExchangeForFeesAndServicesRendered	125000	usd
CY2021Q1	roag	Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue	100000	usd
CY2021Q1	roag	Conversion Of Convertible Notes Payabe And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayabeAndAccruedInterestIntoCommonStock	11001	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-530248	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5522591	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-461239	usd
CY2021Q2	roag	Human Brands International Inc Merge HumanBrandsInternationalIncMerge	22653872	usd
CY2021Q2	roag	Not Issued Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings NotIssuedSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferings	20000	usd
CY2021Q2	roag	Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue	99380	usd
CY2021Q2	roag	Conversion Of Convertible Debentures And Accrued Interest Into Common Stock ConversionOfConvertibleDebenturesAndAccruedInterestIntoCommonStock	680449	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17469871	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-249507	usd
CY2021Q3	roag	Adjustment Adjustment	2	usd
CY2021Q3	roag	Third Parties Investment Closing Pending ThirdPartiesInvestmentClosingPending	201667	usd
CY2021Q3	roag	Conversion Of Convertible Notes Payabe And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayabeAndAccruedInterestIntoCommonStock	201086	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17623120	usd
	roag	Net Loss NetLoss	1230814	usd
	roag	Net Loss NetLoss	566221	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16870	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	35000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	49450	usd
	roag	Common Stock Issued In Exchange For Fees And Services CommonStockIssuedInExchangeForFeesAndServices	40000	usd
	roag	Preferred Stock Issued As Compensation To Employees Officers Andor Directors PreferredStockIssuedAsCompensationToEmployeesOfficersAndorDirectors	-90000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	145000	usd
	roag	Preferred Stock Issued In Exchange For Fees And Services PreferredStockIssuedInExchangeForFeesAndServices	-129961	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-635634	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	104386	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	258600	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-25745	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-234	usd
	roag	Assets Impairement AssetsImpairement	14418	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-520382	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1718718	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	345438	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	114514	usd
	roag	Increase Decrease In Related Party Loans IncreaseDecreaseInRelatedPartyLoans	4350	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	190629	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-110	usd
	roag	Increase Decrease In Contingencias And Commitments IncreaseDecreaseInContingenciasAndCommitments	201667	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1013523	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101408	usd
	roag	Cash Received From Merger Transaction CashReceivedFromMergerTransaction	179815	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	14418	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	194233	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227713	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20000	usd
	us-gaap	Proceeds From Sale Of Loans Receivable ProceedsFromSaleOfLoansReceivable	50000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	60000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	50787	usd
	roag	Proceeds From Short Term Loans ProceedsFromShortTermLoans	-1364501	usd
	roag	Related Party Loan RelatedPartyLoan	-1550	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	12500	usd
	roag	Proceeds From Promissory Note ProceedsFromPromissoryNote	-0	usd
	roag	Proceeds From Promissory Note ProceedsFromPromissoryNote	81500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1163526	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	44231	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	92	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44342	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111	usd
	roag	Common Stock Issued To Reduce Convertible Promissory Notes Payable CommonStockIssuedToReduceConvertiblePromissoryNotesPayable	892536	usd
	roag	Series E Preferred Stock Issued In Lieu Of Cash For Accrued Officer Compensation SeriesEPreferredStockIssuedInLieuOfCashForAccruedOfficerCompensation	225000	usd
	roag	Common Stock Issued In Connection With Acquisition Of Business CommonStockIssuedInConnectionWithAcquisitionOfBusiness	8467377	usd
	roag	Preferred Stock Issued In Connection With Acquisition Of Business PreferredStockIssuedInConnectionWithAcquisitionOfBusiness	10777500	usd
	roag	Nature Of Business NatureOfBusiness	<p id="xdx_84D_ecustom--NatureOfBusiness_ziWQdMJ4qj2l" style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_ztwML3LyDUt2">Nature of Business</span></span></i></span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.95pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rogue One, Inc. (“Rogue One” or the “Company”) is a consumer products and marketing company focused on the high-margin, multi-trillion-dollar alcoholic beverages sector.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.5pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2017, Creative Edge Nutrition, a Nevada corporation ("CEN") and Rogue One executed an asset purchase agreement whereby the Company purchased the assets and liabilities of CEN's subsidiary, Giddy Up Energy Products, Inc. ("Giddy"). As consideration, the Company agreed to exchange 47,197,601 shares of its common stock. On January 24, 2018, the Company completed the distribution of its common shares to the CEN shareholders to consummate the acquisition of Giddy. On December 7, 2020, the Company and Giddy entered into a Settlement Agreement, Waiver and Release of Claims whereby each party warranted and represented that they sought to fully and mutually rescind the purchase agreement dated June 27, 2017 and, in so doing, for Giddy to acquire the assets previously sold and, at the same time, for each of the parties to waive and release all claims, both known and unknown, and to indemnify and hold all other parties harmless. In addition, the parties agreed to enter into an exclusive licensing agreement for the Giddy Up brand in the category of alcoholic beverages.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.85pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 23, 2020, the Company entered into a Merger Agreement and Plan of Reorganization with Human Brands International, Inc., a private corporation organized pursuant to the laws of the State of Nevada (“Human Brands”), pursuant to which, at the effective time, Human Brands shareholders will exchange 100% of the equity in Human Brands in exchange for a majority controlling interest in the Company. On June 30, 2021, the Acquisition Agreement was made effective pending certain closing conditions. Under the terms of the Acquisition Agreement, the Company agreed to issue an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Stock issued during period for acquisitions">45</span> shares of its Series D preferred stock and an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock issued during period for acquisitions">176,771,962</span> shares of its common stock to acquire all of the outstanding capital stock of Human Brands.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.9pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Brands operating divisions currently own and manage over 250,000 agave plants, several premium spirit brands, and hold exclusive import and export rights for a variety of spirit brands. Its core foundation is built upon its bulk tequila production operations. Human Brands currently has supply contracts with well- known tequila brands, celebrities, and athletes.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.75pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 7, 2021, the Company effected a <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20210401__20210407" title="Reverse stock split">1-for-100</span> reverse split which as preceded by a filing of an amendment to its Articles of Incorporation that the Company completed with the Nevada Secretary of State on February 13, 2021. On April 7, 2021, the Company also amended its Articles of Incorporation to change its name to Rogue One, Inc.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2021, the Company entered into that certain Merger Agreement and Plan of Reorganization (the “Acquisition Agreement”) with each of the stockholders of Human Brands International, Inc., a Nevada corporation (the “Acquired Company” or “Human Brands”), finishing the merger initiated on September 23, 2020.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Acquisition Agreement, the Company agreed to issue an aggregate of forty-seven (47) shares of Series D Preferred Stock (par value $0.001) (the “Preferred Shares”) and an aggregate of One Hundred Seventy-Six Million Seven Hundred Seventy-One Thousand Nine Hundred Sixty-Two (176,771,962) shares of Common Stock (par value $0.001) (the “Common Shares”) to acquire all of the outstanding capital stock of the Acquired Company.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Acquisition Agreement was the product of several months of meetings and due diligence conducted by the Company’s officers and directors that resulted in successful negotiations with the officers and directors of the Acquired Company and the stockholders of the Acquired Company.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not employ or utilize the services of any investment banker, advisor, or other third party in connection with the Acquisition Agreement, the transactions underlying the Acquisition Agreement or both of them. As a result, the Company did not incur or pay any fees to any investment banker, advisor, or other third party but may ignored critically important aspects of the business conducted by the Acquired Company that we may later discover with materially adverse consequences to the Company’s financial condition for an indefinite period of time.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Preferred Shares and all of the Common Shares that were issued in accordance with the Acquisition Agreement are “unregistered securities” in that they were issued pursuant to claims of exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 506(b) promulgated by the Securities and Exchange Commission thereunder as well as certain claims to the qualification requirements under state securities laws in the states wherein the holders of all of the outstanding capital stock of the Acquired Company. Moreover, all of the Preferred Shares and all of the Common Shares that were issued pursuant to the Acquisition Agreement were issued with a restricted securities legend and only then after we received certain additional written assurances from the stockholders of the Acquired Company.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Brands was founded in late 2014 with a plan to capitalize in perceived growth prospects in the consumer alcoholic products industry. In recent years Human Brands has focused on the tequila products segment within that industry as management believes that the tequila products segment may offer stronger sales growth opportunities relative to other consumer alcoholic segments. The management of Human Brands follows a “ground to glass” strategy that, in practical terms, means that management attempts to control marketing, sales, and assets throughout the selection of raw materials (the agave plants) and the operation of the manufacturing process. The strategy also involves selection and constant management of the marketing channels, advertising programs, and target marketing strategies. Human Brands has had to confront ever-rising costs for raw materials as agave prices have increased by about 694% since 2016.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently Human Brands has approximately 400,000 agave plants and has adopted a strategy to grow more agave plants to ensure that the company has a stable supply of raw materials and at price levels that may serve to insulate the company from excessive price increases in the market. The company has adopted a two-part strategy: (a) sell agave plants to generate revenues; and (b) at the same time, use agave produced by the company’s own agave plants as raw material for the company’s tequila products. The Company believes that, if circumstances allow, this strategy may serve to insulate the company from some of the excessive cost pressures in the raw agave market.</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646"><b>Cautionary Statement </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">on </span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646">Forward-Looking Statements</span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">All statements, other than statements </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">current or historical fact, contained </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">this filing are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">"goal," "may," "will," "would," "could," </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">"should," </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">"can," </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">"continue" and other similar words or expressions </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">(and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">the negative thereof). Rogue One, Inc., and its subsidiaries </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">(Rogue, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">including </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">statements about the impact of our recently completed acquisition of Human Brands International, Inc., and its subsidiaries</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">(</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">the Human Brands Acquisition), and future acquisitions, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">investments </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">adequacy of our available cash resources. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">These </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">statements may be found in the various sections of this filing, such as Part I, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations." and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">Part </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">II, These forward-looking statements </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">reflect </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C; line-height: 115%">of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">historical trends, current conditions, business </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">strategies, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">may </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">cause our or our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">industry's </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">actual results, levels of activity, performance or achievements to be materially different from any </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646; line-height: 115%">future </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F; line-height: 115%">results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%"> </span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 2.5pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">All forward-looking statements included in this Notes are based on information available to us </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1C1C1C">on </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">the date of this filing. Except as may be otherwise required by law, we undertake </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646">no </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">obligation to update or revise the forward-looking statements included in this filing, whether as a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646">result </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">of new information, future events or otherwise, after </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #464646">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">date of this filing. You should not place undue reliance on any</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B">forward-looking statements, as actual results </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B">may differ </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B">materially </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B">from projections, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B">estimates, or other forward-looking statements due to a variety of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B">important </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B">factors, variables and events including, but </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B">not limited to:</span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 2.5pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B"/></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The impact of COVID-19 on global markets, economic conditions, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the healthcare </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">industry and our results of operations and the response by governments and other </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">third </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">parties.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The risk that regulatory or other approvals </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">required </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">for the HBI </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Acquisition </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">may be delayed or not obtained or are obtained subject </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">conditions that are not anticipated that could require </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">exertion of management's time and our resources or otherwise have an adverse effect on us.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The possibility </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">certain conditions </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">to the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">consummation of the HBI Acquisition will not be satisfied or completed on a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">timely </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">basis and accordingly </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">HBI Acquisition may not be consummated on a timely basis or at all.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Uncertainty as </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">to the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">expected financial performance of the combined company following completion of the HBI Acquisition.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">possibility </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">that the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">expected synergies and value creation from the HBI Acquisition will not be </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">realized or</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">will not be </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">realized </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">within </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">applicable expected </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">time </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">periods.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The exertion of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">management's </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">time and our resources, and other expenses incurred, and business changes required, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">connection with complying with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">undertakings in connection with any regulatory, governmental or third-party consents or approvals for the HBI Acquisition.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The risk </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">unexpected costs will </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">be </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">incurred in connection with the completion and/or </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">integration </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">of the HBI Acquisition or </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">that the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">integration of its subsidiaries will be more difficult or time consuming than </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">expected.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">risk that potential </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">litigation in connection with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">HBI Acquisition </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">may </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">affect </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the timing </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">or occurrence of the HBI Acquisition or result in significant costs of defense, indemnification and liability.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">A </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">downgrade </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">of the credit rating of our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">indebtedness, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">which could give </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">rise </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">to an obligation to redeem existing indebtedness.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">The inability </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">to retain key personnel.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Disruption from </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">announcement, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">pendency </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and/or completion and/or integration of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">HBI Acquisition or the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">integration </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">of the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">subsidiaries</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">, or similar risks from other acquisitions we </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">may </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">announce or complete from time to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">time, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">including </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">potential adverse </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">reactions or changes to business relationships with customers, employees, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">suppliers </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">or regulators, making it more </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">difficult </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">maintain </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">business and operational relationships.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">ability </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">to accurately predict and effectively manage health </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">benefits </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and other operating expenses and reserves,</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Competition.</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Membership and revenue declines or unexpected trends.</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Changes </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">in the beverage industry </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">practices, new technologies, and advances in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">processing and distillation methods.</span></td></tr> </table> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Increased </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">feedstock costs.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Changes </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">in economic, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">political </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">or market conditions.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Changes </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">federal or state laws or regulations, including changes with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">respect to income tax </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">reform or government beverage industry </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">programs </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">as well as changes with and any regulations enacted thereunder that may </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">result </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">from changing political conditions, the new administration or judicial actions.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Our ability </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">adequately </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">price </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">products.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Tax </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">matters.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Disasters or major </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">epidemics.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Changes </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">in expected </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">contract start dates.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Provider, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">state, federal, foreign, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">other contract changes and timing of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">regulatory </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">approval of contracts.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">The difficulty </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">of predicting the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">timing </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">or outcome of pending or future </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">legal </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and regulatory proceedings or government investigations.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">Challenges </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">our contract awards.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">Cyber-attacks </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">or other privacy or data security incidents.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">possibility </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">the expected </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">synergies </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and value creation from acquired </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">businesses, including businesses </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">we may acquire in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">future, will not be realized, or will </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">not </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">be </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">realized </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">within the expected </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">time </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">period.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">The </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">exertion of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">management's </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">time and our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">resources, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and other expenses </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">incurred, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">and business changes </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">required </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">in connection with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">complying </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">undertakings </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">in </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">connection with any </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">regulatory, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">governmental or third-party consents or approvals for </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">acqu</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #5E5D5D; line-height: 115%">i</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A2B; line-height: 115%">sitions.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-right: 14.2pt; padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">Disruption </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">caused by significant completed and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">pending </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">acquisitions making it more difficult to maintain business and operational </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">relationships.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">The risk that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">unexpected costs will be incurred in connection with the completion and/or </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">integration </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">of acquisition transactions.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">Changes in expected closing dates, estimated </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">purchase </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">price and accretion for </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">acquisitions.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">The risk that acquired businesses will not be integrated successfully.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">Restrictions and limitations in connection with our indebtedness.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">Availability of debt and equity financing, on </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">terms that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">are </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444; line-height: 115%">favorable to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">us.</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">Inflation; and</span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #3B3B3B; line-height: 115%">•</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31; line-height: 115%">Foreign currency fluctuations.</span></td></tr> </table> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">This list of important factors is not intended to be exhaustive. We discuss certain of these matters more </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">fully, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">as </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">well </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">as certain other factors that may affect our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">business </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">operations, financial condition and results of operations, in our filings with </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">Securities </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">and Exchange </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">Commission (SEC), including quarterly reports on Form 10-Q and current reports on Form 8-K. Item </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">1A. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #181818">"Ris</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">k </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">Factors" of Part </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">I </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">this </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">Notes contains a further discussion of these and other important factors </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">that </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">could cause actual results to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">differ from </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">expectations. Due to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">these </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">important </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">factors </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">risks, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">we cannot give assurances with respect </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">our future performance, including without limitation our ability </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #444444">to maintain </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #312F31">adequate premium levels or our ability to control our future cultivation, harvesting, distillation and selling, general and administrative costs.</span></p> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-100
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17400000	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zqc16KJnbjh5" style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zjPRSjv6C604">Use of Estimates</span></span></i></span></p> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.8pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p>
CY2021Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	roag	Net Income Loss Applicable To Common Shareholders NetIncomeLossApplicableToCommonShareholders	-1230814	usd
	roag	Net Income Loss Applicable To Common Shareholders NetIncomeLossApplicableToCommonShareholders	-3242490	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115739401	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97081861	shares
	roag	Convertible Preferred Stock ConvertiblePreferredStock	250000000	shares
	roag	Convertible Preferred Stock ConvertiblePreferredStock	100000000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	365739401	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197081861	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	roag	Net Loss NetLoss	1230814	usd
CY2021Q3	roag	Working Capital Deficit WorkingCapitalDeficit	6269364	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	15900941	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44342	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111	usd
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	826297	usd
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	3408995	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	298079	usd
CY2021Q3	roag	Account Receivable130 AccountReceivable130	174568	usd
CY2021Q3	roag	Account Receivable3160 AccountReceivable3160	54731	usd
CY2021Q3	roag	Account Receivable6190 AccountReceivable6190	66657	usd
CY2021Q3	roag	Account Receivable91 And Over AccountReceivable91AndOver	232262	usd
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	826297	usd
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13253	usd
CY2021Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	94171	usd
CY2021Q3	roag	Inventory Biological Assets InventoryBiologicalAssets	6889130	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	6996553	usd
	roag	Total Equity Value TotalEquityValue	7432862	usd
	roag	Market Value Equity MarketValueEquity	11033306	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315300	usd
	us-gaap	Depreciation Depreciation	16870	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	331846	usd
CY2021Q3	us-gaap	Depreciation Depreciation	16870	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16870	usd
CY2021Q3	roag	Net Value NetValue	314976	usd
CY2021Q3	roag	Prepayments Prepayments	120000	usd
CY2021Q3	us-gaap	Security Deposit SecurityDeposit	2195	usd
CY2021Q3	roag	Security Deposits Rent SecurityDepositsRent	3903	usd
CY2021Q3	roag	Janon Costley JanonCostley	1250	usd
CY2021Q3	roag	Creditable Paid Iva CreditablePaidIva	129	usd
CY2021Q3	roag	Creditable Paid Ieps CreditablePaidIeps	151	usd
CY2021Q3	roag	Iva Pending IvaPending	42	usd
CY2021Q3	roag	Ieps Pending IepsPending	410	usd
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	128080	usd
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2021Q3	us-gaap	Goodwill Goodwill	10804239	usd
CY2021Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2934454	usd
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2298820	usd
	roag	Schedule Of Fair Value Of Assumptions Used ScheduleOfFairValueOfAssumptionsUsed	<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssumptionsUsed_zBS5sWJ2Bza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES PAYABLE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"><span id="xdx_8B1_zQdXOJk71dul" style="display: none">Schedule of fair value of assumptions used</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center"><b> </b></td> <td colspan="3" style="text-align: center"><b>December 31,</b></td><td style="text-align: center"><b> </b></td> <td colspan="3" style="text-align: center"><b>December 31,</b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Expected dividend yield (1)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20210930_fKDEp_zSDVqGLO0egf" title="Expected dividend yield">0.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20201231_fKDEp_zQ8pOic1RZna" title="Expected dividend yield">0.00</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Risk-free interest rate (2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_fKDIp_zmusxBLSsd46" title="Risk-free interest rate">0.05</span> – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_fKDIp_z5vLUyuMz4yg" title="Risk-free interest rate">0.07</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_fKDIp_zDqbKuEGzXD2" title="Risk-free interest rate">0.09</span> – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_fKDIp_z77Pn2TQ6U2c" title="Risk-free interest rate">0.17</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Expected volatility (3)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_fKDMp_zGnIqITwdyVk" title="Expected volatility">253.5</span> – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_fKDMp_zDq3WE3uHEc9" title="Expected volatility">415.6</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_fKDMp_z3kyoC4pFRvb" title="Expected volatility">199.52 </span>– <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_fKDMp_zgvBGEj2OiXd" title="Expected volatility">582.91</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zzbwfdHs0dl7" title="Expected life (in years)">0.5</span> – <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_zXFW0IfNEnh" title="Expected life (in years)">1.0</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zAL1wljeWhYe" title="Expected life (in years)">0.5</span> – <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zXb4H2jq7G1h" title="Expected life (in years)">1.0</span></span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 5.75pt 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">(1)</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">The Company has no history or expectation of paying cash dividends on its common <span style="letter-spacing: -0.1pt">stock.</span></span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">(2)</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the promissory notes in effect at the time of <span style="letter-spacing: -0.1pt">issuance.</span></span></td></tr> </table> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">(3)</span></td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 115%">The volatility of the Company’s common stock is based on trading activity for the previous contractual term ended at each promissory note issuance <span style="letter-spacing: -0.1pt">date.</span></span></td></tr> </table>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	roag	Revenues From Related Parties RevenuesFromRelatedParties	1198434	usd
CY2020	roag	Revenues From Related Parties RevenuesFromRelatedParties	1931303	usd
CY2019	roag	Revenues From Related Parties RevenuesFromRelatedParties	110244	usd
CY2021Q3	roag	Principal Value Of Convertible Notes PrincipalValueOfConvertibleNotes	1316584	usd
CY2020Q4	roag	Principal Value Of Convertible Notes PrincipalValueOfConvertibleNotes	1595553	usd
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	35750	usd
CY2021Q3	roag	Other Convertibles OtherConvertibles	169364	usd
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1485948	usd
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1559803	usd
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1559803	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	33750	usd
	roag	Conversion Of Principal Amounts Outstanding Into Common Stock Of Company ConversionOfPrincipalAmountsOutstandingIntoCommonStockOfCompany	-276969	usd
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1485948	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1402488	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3242490	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1402488	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-3242490	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	1402488	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	3242490	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5072195	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3080727	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5072195	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3080727	usd
CY2020Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2298820	usd
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	2298820	usd
	roag	Schedule Of Changes In Derivative Liabilities At Fair Value ScheduleOfChangesInDerivativeLiabilitiesAtFairValue	<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfChangesInDerivativeLiabilitiesAtFairValue_zAvbYIvBRdfk" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"> <tr> <td colspan="3" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt"><b>Schedule of Changes in Derivative Liabilities at Fair Value</b></span></td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td colspan="2" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning balance, January 1, 2021</span></td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pp0p0_c20210101__20210930_zijchLw3WFE1" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1547">-</span> </span></td></tr> <tr style="background-color: white"> <td colspan="4" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of embedded conversion features of convertible promissory notes included in earnings</span></td> <td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c20210101__20210930_pp0p0" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Change in fair value of embedded conversion features of convertible promissory notes and warrants included in earnings"><span style="-sec-ix-hidden: xdx2ixbrl1549">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td colspan="4" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embedded conversion option liability recorded in connection with the issuance of convertible promissory notes</span></td> <td id="xdx_982_ecustom--RecordNonCashDerivativeLiabilityOnNotes_c20210101__20210930_pp0p0" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Embedded conversion option & warrant liability recorded in connection with the issuance of convertible promissory notes"><span style="-sec-ix-hidden: xdx2ixbrl1551">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; width: 66%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ending balance, September 30, 2021</span></td> <td style="white-space: nowrap; vertical-align: bottom; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="white-space: nowrap; vertical-align: bottom; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="white-space: nowrap; vertical-align: bottom; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pp0p0_c20210101__20210930_zx9FVr8gBo97" style="border-top: black 1pt solid; border-bottom: black 2.25pt double; white-space: nowrap; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1553">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table>

dei

Entity Central Index Key

EntityCentralIndexKey

0001058330

dei

Amendment Flag

AmendmentFlag

false

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2021

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q3

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2020Q4

roag

Accounts Receivable

AccountsReceivable

usd

CY2020Q4

us-gaap

Inventory Net

InventoryNet

usd

CY2020Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

usd

CY2020Q4

roag

Fully Controlled Companies

FullyControlledCompanies

usd

CY2020Q4

roag

Associated Companies

AssociatedCompanies

usd

CY2020Q4

roag

Shares Publicly Traded Srsg

SharesPubliclyTradedSrsg

usd

CY2020Q4

roag

Property Plant And Equipment

PropertyPlantAndEquipment

usd

CY2020Q4

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

usd

CY2020Q4

us-gaap

Goodwill

usd

CY2020Q4

roag

Assets Pledged

AssetsPledged

usd

CY2020Q4

us-gaap

Assets Noncurrent

AssetsNoncurrent

usd

CY2020Q4

us-gaap

Employee Related Liabilities Current

EmployeeRelatedLiabilitiesCurrent

usd

CY2020Q4

roag

Related Party Loans

RelatedPartyLoans

usd

CY2020Q4

us-gaap

Notes And Loans Payable Current

NotesAndLoansPayableCurrent

usd

CY2021Q3

us-gaap

Operating Lease Liability Noncurrent

OperatingLeaseLiabilityNoncurrent

usd

CY2020Q4

roag

Sba Loan

SbaLoan

usd

CY2021Q3

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

usd

CY2020Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

usd

CY2021Q3

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2020Q4

us-gaap

Minority Interest

MinorityInterest

usd

CY2021Q3

roag

Preferred Stock Series D0.00001 Par Value.1 Share Authorized1 And Zero Shares Issued And Outstanding As Of December312018 And2017 Respectively1

PreferredStockSeriesD0.00001ParValue.1ShareAuthorized1AndZeroSharesIssuedAndOutstandingAsOfDecember312018And2017Respectively1

usd

CY2020Q4

roag

Preferred Stock Series D0.00001 Par Value.1 Share Authorized1 And Zero Shares Issued And Outstanding As Of December312018 And2017 Respectively1

PreferredStockSeriesD0.00001ParValue.1ShareAuthorized1AndZeroSharesIssuedAndOutstandingAsOfDecember312018And2017Respectively1

usd

CY2021Q3

roag

Preferred Stock Series E0.00001 Par Value.12 Shares Authorized12 And Zero Shares Issued And Outstanding As Of December312019 And2018 Respectively

PreferredStockSeriesE0.00001ParValue.12SharesAuthorized12AndZeroSharesIssuedAndOutstandingAsOfDecember312019And2018Respectively

usd

CY2020Q4

roag

Preferred Stock Series E0.00001 Par Value.12 Shares Authorized12 And Zero Shares Issued And Outstanding As Of December312019 And2018 Respectively

PreferredStockSeriesE0.00001ParValue.12SharesAuthorized12AndZeroSharesIssuedAndOutstandingAsOfDecember312019And2018Respectively

usd

CY2021Q3

us-gaap

Common Stock Value

CommonStockValue

usd

CY2020Q4

us-gaap

Common Stock Value

CommonStockValue

usd

CY2020Q3

us-gaap

Revenues

usd

us-gaap

Revenues

usd

CY2020Q3

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

usd

CY2020Q3

us-gaap

Gross Profit

GrossProfit

usd

us-gaap

Gross Profit

GrossProfit

usd

CY2021Q3

roag

Board Member Fees

BoardMemberFees

usd

roag

Board Member Fees

BoardMemberFees

usd

CY2021Q3

us-gaap

Professional Fees

ProfessionalFees

usd

us-gaap

Professional Fees

ProfessionalFees

usd

CY2020Q3

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

usd

CY2021Q3

roag

Derivative Liability Expense

DerivativeLiabilityExpense

usd

roag

Derivative Liability Expense

DerivativeLiabilityExpense

usd

CY2020Q3

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

usd

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

usd

CY2021Q3

roag

Tequila Armero S.A De C.V

TequilaArmeroS.aDeC.v

usd

CY2020Q3

roag

Tequila Armero S.A De C.V

TequilaArmeroS.aDeC.v

usd

roag

Tequila Armero S.A De C.V

TequilaArmeroS.aDeC.v

usd

CY2020Q3

roag

Industrias Naturales De Tequilas S.A De C.V

IndustriasNaturalesDeTequilasS.aDeC.v

usd

roag

Industrias Naturales De Tequilas S.A De C.V

IndustriasNaturalesDeTequilasS.aDeC.v

usd

CY2020Q3

roag

Tequila Copter S.A.De C.V

TequilaCopterS.a.DeC.v

usd

roag

Tequila Copter S.A.De C.V

TequilaCopterS.a.DeC.v

usd

CY2020Q3

roag

Sobre Todo Alimentacion S.A.De C.V

SobreTodoAlimentacionS.a.DeC.v

usd

roag

Sobre Todo Alimentacion S.A.De C.V

SobreTodoAlimentacionS.a.DeC.v

usd

CY2020Q3

roag

Turasu Spr De Rl

TurasuSprDeRl

usd

roag

Turasu Spr De Rl

TurasuSprDeRl

usd

CY2020Q3

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

usd

CY2020Q2

roag

Conversion Of Series D Preferred Stock For Common Stock

ConversionOfSeriesDPreferredStockForCommonStock

usd

CY2021Q1

roag

Return Of Common Stock Issued In Connection With Acquisition Of Business

ReturnOfCommonStockIssuedInConnectionWithAcquisitionOfBusiness

usd

CY2021Q1

roag

Conversion Of Series E Preferred Stock For Common Stock

ConversionOfSeriesEPreferredStockForCommonStock

usd

CY2021Q3

roag

Not Issued Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings

NotIssuedSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferings

usd

CY2021Q3

roag

Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value

IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

usd

roag

Common Stock Issued In Exchange For Fees And Services

CommonStockIssuedInExchangeForFeesAndServices

usd

roag

Preferred Stock Issued As Compensation To Employees Officers Andor Directors

PreferredStockIssuedAsCompensationToEmployeesOfficersAndorDirectors

usd

roag

Preferred Stock Issued In Exchange For Fees And Services

PreferredStockIssuedInExchangeForFeesAndServices

usd

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

usd

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

usd

roag

Increase Decrease In Other Investments Associated Companies

IncreaseDecreaseInOtherInvestmentsAssociatedCompanies

usd

roag

Increase Decrease In Other Investments Associated Companies

IncreaseDecreaseInOtherInvestmentsAssociatedCompanies

usd

us-gaap

Increase Decrease In Other Current Assets

IncreaseDecreaseInOtherCurrentAssets

usd

roag

Assets Impairement

AssetsImpairement

usd

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

usd

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

usd

roag

Increase Decrease In Related Party Loans

IncreaseDecreaseInRelatedPartyLoans

usd

us-gaap

Increase Decrease In Employee Related Liabilities

IncreaseDecreaseInEmployeeRelatedLiabilities

usd

us-gaap

Increase Decrease In Other Current Liabilities

IncreaseDecreaseInOtherCurrentLiabilities

usd

roag

Increase Decrease In Contingencias And Commitments

IncreaseDecreaseInContingenciasAndCommitments

usd

roag

Cash Received From Merger Transaction

CashReceivedFromMergerTransaction

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

usd

us-gaap

Proceeds From Sale Of Loans Receivable

ProceedsFromSaleOfLoansReceivable

usd

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

usd

us-gaap

Proceeds From Notes Payable

ProceedsFromNotesPayable

usd

roag

Proceeds From Short Term Loans

ProceedsFromShortTermLoans

usd

roag

Related Party Loan

RelatedPartyLoan

usd

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

usd

us-gaap

Interest Paid

InterestPaid

usd

us-gaap

Interest Paid

InterestPaid

usd

roag

Common Stock Issued To Reduce Convertible Promissory Notes Payable

CommonStockIssuedToReduceConvertiblePromissoryNotesPayable

usd

roag

Series E Preferred Stock Issued In Lieu Of Cash For Accrued Officer Compensation

SeriesEPreferredStockIssuedInLieuOfCashForAccruedOfficerCompensation

usd

roag

Common Stock Issued In Connection With Acquisition Of Business

CommonStockIssuedInConnectionWithAcquisitionOfBusiness

usd

roag

Preferred Stock Issued In Connection With Acquisition Of Business

PreferredStockIssuedInConnectionWithAcquisitionOfBusiness

usd

roag

Conversion Of Related Party Debt

ConversionOfRelatedPartyDebt

usd

roag

Conversion Of Related Party Debt

ConversionOfRelatedPartyDebt

usd

roag

Capital Lease Additions To Fixed Assets

CapitalLeaseAdditionsToFixedAssets

usd

roag

Capital Lease Additions To Fixed Assets

CapitalLeaseAdditionsToFixedAssets

usd

roag

Convertible Promissory Notes

ConvertiblePromissoryNotes

shares

roag

Convertible Promissory Notes

ConvertiblePromissoryNotes

shares

us-gaap

Stock Issued During Period Value Conversion Of Convertible Securities

StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

usd

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

usd

us-gaap

Income Tax Reconciliation State And Local Income Taxes

IncomeTaxReconciliationStateAndLocalIncomeTaxes

usd

roag

Accrued Expense Benefit

AccruedExpenseBenefit

usd

roag

Accrued Expense Benefit

AccruedExpenseBenefit

usd

CY2021Q3

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

usd

CY2020Q4

us-gaap

Deferred Tax Assets Liabilities Net

DeferredTaxAssetsLiabilitiesNet

usd

CY2021Q3

us-gaap

Embedded Derivative Fair Value Of Embedded Derivative Liability

EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability

usd

CY2021Q3

us-gaap

Derivative Liabilities

DerivativeLiabilities

usd

CY2020Q4

us-gaap

Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs

FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs

usd

us-gaap

Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings

FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings

usd

roag

Record Non Cash Derivative Liability On Notes

RecordNonCashDerivativeLiabilityOnNotes

usd

CY2021Q3

us-gaap

Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs

FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs

usd

dei

Document Type

DocumentType

10-Q

dei

Document Quarterly Report

DocumentQuarterlyReport

true

dei

Document Period End Date

DocumentPeriodEndDate

2021-09-30

dei

Document Transition Report

DocumentTransitionReport

false

dei

Entity File Number

EntityFileNumber

00-24723

dei

Entity Registrant Name

EntityRegistrantName

ROGUE ONE, INC.

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

NV

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

88-0393257

dei

Entity Address Address Line1

EntityAddressAddressLine1

1023 K Street, N.W.

dei

Entity Address Address Line2

EntityAddressAddressLine2

Suite 454

dei

Entity Address City Or Town

EntityAddressCityOrTown

Washington

dei

Entity Address State Or Province

EntityAddressStateOrProvince

DC

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

2005

dei

City Area Code

CityAreaCode

405

dei

Local Phone Number

LocalPhoneNumber

733-1567

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

dei

Entity Small Business

EntitySmallBusiness

true

dei

Entity Filer Category

EntityFilerCategory

Non-accelerated Filer

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q1

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

312655147

shares

CY2021Q3

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

44342

usd

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

111

usd

CY2021Q3

roag

Accounts Receivable

AccountsReceivable

826297

usd

CY2021Q3

us-gaap

Inventory Net

InventoryNet

6996553

usd

CY2021Q3

us-gaap

Other Assets Current

OtherAssetsCurrent

128080

usd

CY2021Q3

roag

Fully Controlled Companies

FullyControlledCompanies

8400

usd

CY2021Q3

roag

Associated Companies

AssociatedCompanies

703740

usd

CY2021Q3

roag

Shares Publicly Traded Srsg

SharesPubliclyTradedSrsg

7432862

usd

CY2021Q3

us-gaap

Assets Current

AssetsCurrent

16140274

usd

CY2020Q4

us-gaap

Assets Current

AssetsCurrent

111

usd

CY2021Q3

roag

Property Plant And Equipment

PropertyPlantAndEquipment

314976

usd

CY2021Q3

roag

Loans

50000

usd

CY2021Q3

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

94411

usd

CY2021Q3

us-gaap

Goodwill

10804239

usd

CY2021Q3

roag

Assets Pledged

AssetsPledged

246102

usd

CY2021Q3

us-gaap

Assets Noncurrent

AssetsNoncurrent

11509728

usd

CY2021Q3

us-gaap

Assets

27650002

usd

CY2020Q4

us-gaap

Assets

111

usd

CY2021Q3

us-gaap

Accounts Payable Current

AccountsPayableCurrent

1785337

usd

CY2020Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

165466

usd

CY2021Q3

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

1678775

usd

CY2020Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

1555862

usd

CY2021Q3

us-gaap

Employee Related Liabilities Current

EmployeeRelatedLiabilitiesCurrent

346020

usd

CY2021Q3

roag

Related Party Loans

RelatedPartyLoans

351233

usd

CY2021Q3

us-gaap

Notes And Loans Payable Current

NotesAndLoansPayableCurrent

526768

usd

CY2021Q3

roag

Notes Payable Third Party

NotesPayableThirdParty

12500

usd

CY2021Q3

roag

Notes Payable Related Party

NotesPayableRelatedParty

6055

usd

CY2021Q3

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

131678082

shares

CY2020Q4

roag

Notes Payable Related Party

NotesPayableRelatedParty

4505

usd

CY2021Q3

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

1485948

usd

CY2020Q4

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

1559803

usd

CY2021Q3

roag

Convertible Notes Payable Accrued Interest

ConvertibleNotesPayableAccruedInterest

743643

usd

CY2021Q3

us-gaap

Derivative Liabilities Current

DerivativeLiabilitiesCurrent

2934454

usd

CY2020Q4

us-gaap

Derivative Liabilities Current

DerivativeLiabilitiesCurrent

2298820

usd

CY2021Q3

us-gaap

Bank Overdrafts

BankOverdrafts

179

usd

CY2021Q3

us-gaap

Liabilities Current

LiabilitiesCurrent

9870910

usd

CY2020Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

5584456

usd

CY2021Q3

roag

Sba Loan

SbaLoan

155972

usd

CY2021Q3

us-gaap

Liabilities

10026882

usd

CY2020Q4

us-gaap

Liabilities

5584456

usd

CY2021Q3

roag

Common Stock To Be Issued

CommonStockToBeIssued

378439

usd

CY2021Q3

roag

Preferred Shares Series E Conversion Rights

PreferredSharesSeriesEConversionRights

225000

usd

CY2021Q3

roag

Apic On Shares To Be Issued

ApicOnSharesToBeIssued

18843105

usd

CY2021Q3

us-gaap

Minority Interest

MinorityInterest

3408995

usd

CY2021Q3

roag

Preferred Stock Serieis Par Value

PreferredStockSerieisParValue

0.00001

CY2020Q4

roag

Preferred Stock Serieis Par Value

PreferredStockSerieisParValue

0.00001

CY2021Q3

roag

Preferred Stock Serieis Authorized

PreferredStockSerieisAuthorized

69999990

shares

CY2021Q3

roag

Preferred Stock Serieis Issued

PreferredStockSerieisIssued

10000000

shares

CY2021Q3

roag

Preferred Stock Serieis Outstanding

PreferredStockSerieisOutstanding

10000000

shares

CY2020Q4

roag

Preferred Stock Serieis Issued

PreferredStockSerieisIssued

10000000

shares

CY2020Q4

roag

Preferred Stock Serieis Outstanding

PreferredStockSerieisOutstanding

10000000

shares

CY2021Q3

us-gaap

Preferred Stock Value

PreferredStockValue

100

usd

CY2020Q4

us-gaap

Preferred Stock Value

PreferredStockValue

100

usd

CY2021Q3

roag

Preferred Stock Serieis D Par Value

PreferredStockSerieisDParValue

0.00001

CY2020Q4

roag

Preferred Stock Serieis D Par Value

PreferredStockSerieisDParValue

0.00001

CY2021Q3

roag

Preferred Stock Serieis D Authorized

PreferredStockSerieisDAuthorized

1

shares

CY2020Q4

roag

Preferred Stock Serieis D Authorized

PreferredStockSerieisDAuthorized

1

shares

CY2021Q3

roag

Preferred Stock Serieis D Issued

PreferredStockSerieisDIssued

0

shares

CY2021Q3

roag

Preferred Stock Serieis D Outstanding

PreferredStockSerieisDOutstanding

0

shares

CY2020Q4

roag

Preferred Stock Serieis D Issued

PreferredStockSerieisDIssued

0

shares

CY2020Q4

roag

Preferred Stock Serieis D Outstanding

PreferredStockSerieisDOutstanding

0

shares

CY2021Q3

roag

Preferred Stock Serieis E Par Value

PreferredStockSerieisEParValue

0.00001

CY2020Q4

roag

Preferred Stock Serieis E Par Value

PreferredStockSerieisEParValue

0.00001

CY2021Q3

roag

Preferred Stock Serieis E Authorized

PreferredStockSerieisEAuthorized

50

shares

CY2020Q4

roag

Preferred Stock Serieis E Authorized

PreferredStockSerieisEAuthorized

50

shares

CY2021Q3

roag

Preferred Stock Serieis E Issued

PreferredStockSerieisEIssued

48

shares

CY2021Q3

roag

Preferred Stock Serieis E Outstanding

PreferredStockSerieisEOutstanding

48

shares

CY2020Q4

roag

Preferred Stock Serieis E Outstanding

PreferredStockSerieisEOutstanding

20

shares

CY2020Q4

roag

Preferred Stock Serieis E Outstanding

PreferredStockSerieisEOutstanding

20

shares

CY2021Q3

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2020Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2021Q3

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

1000000000

shares

CY2020Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

1000000000

shares

CY2021Q3

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

131678082

shares

CY2020Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

101925194

shares

CY2020Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

101925194

shares

CY2021Q3

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

10536740

usd

CY2020Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

8984757

usd

CY2021Q3

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-15900941

usd

CY2020Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-14670127

usd

CY2021Q3

roag

Total Stockholders Equity

TotalStockholdersEquity

17623120

usd

CY2020Q4

roag

Total Stockholders Equity

TotalStockholdersEquity

-5583345

usd

CY2021Q3

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

27650002

usd

CY2020Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

111

usd

CY2021Q3

us-gaap

Revenues

1198434

usd

us-gaap

Revenues

1198434

usd

CY2021Q3

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1019678

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

1019678

usd

CY2021Q3

us-gaap

Gross Profit

GrossProfit

178755

usd

us-gaap

Gross Profit

GrossProfit

178755

usd

CY2020Q3

roag

Board Member Fees

BoardMemberFees

15000

usd

roag

Board Member Fees

BoardMemberFees

45000

usd

CY2021Q3

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

300986

usd

CY2020Q3

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

43678

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

688529

usd

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

61429

usd

CY2020Q3

us-gaap

Professional Fees

ProfessionalFees

9000

usd

us-gaap

Professional Fees

ProfessionalFees

76935

usd

CY2021Q3

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

16870

usd

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

16870

usd

CY2021Q3

us-gaap

Operating Expenses

OperatingExpenses

317857

usd

CY2020Q3

us-gaap

Operating Expenses

OperatingExpenses

67678

usd

us-gaap

Operating Expenses

OperatingExpenses

705400

usd

us-gaap

Operating Expenses

OperatingExpenses

183364

usd

CY2021Q3

us-gaap

Operating Income Loss

OperatingIncomeLoss

-139101

usd

CY2020Q3

us-gaap

Operating Income Loss

OperatingIncomeLoss

-67678

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

-526644

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

-183364

usd

CY2020Q3

roag

Derivative Liability Expense

DerivativeLiabilityExpense

27713

usd

roag

Derivative Liability Expense

DerivativeLiabilityExpense

129961

usd

CY2021Q3

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-187035

usd

CY2020Q3

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-137316

usd

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-635633

usd

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

-2730012

usd

CY2021Q3

us-gaap

Interest Expense

InterestExpense

72189

usd

CY2020Q3

us-gaap

Interest Expense

InterestExpense

76212

usd

us-gaap

Interest Expense

InterestExpense

212513

usd

us-gaap

Interest Expense

InterestExpense

199153

usd

roag

Other Income Expenses

OtherIncomeExpenses

-4842

usd

CY2021Q3

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

-14418

usd

us-gaap

Asset Impairment Charges

AssetImpairmentCharges

-14418

usd

CY2021Q3

roag

Liabilities Writeoff

LiabilitiesWriteoff

163236

usd

roag

Liabilities Writeoff

LiabilitiesWriteoff

163236

usd

CY2021Q3

us-gaap

Other Expenses

OtherExpenses

110406

usd

CY2020Q3

us-gaap

Other Expenses

OtherExpenses

241241

usd

us-gaap

Other Expenses

OtherExpenses

704170

usd

us-gaap

Other Expenses

OtherExpenses

3059126

usd

CY2021Q3

us-gaap

Profit Loss

ProfitLoss

-249507

usd

CY2020Q3

us-gaap

Profit Loss

ProfitLoss

-308919

usd

us-gaap

Profit Loss

ProfitLoss

-1230814

usd

us-gaap

Profit Loss

ProfitLoss

-3242490

usd

CY2021Q3

roag

Industrias Naturales De Tequilas S.A De C.V

IndustriasNaturalesDeTequilasS.aDeC.v

19080

usd

roag

Industrias Naturales De Tequilas S.A De C.V

IndustriasNaturalesDeTequilasS.aDeC.v

19080

usd

CY2021Q3

roag

Tequila Copter S.A.De C.V

TequilaCopterS.a.DeC.v

20426

usd

roag

Tequila Copter S.A.De C.V

TequilaCopterS.a.DeC.v

20426

usd

CY2021Q3

roag

Sobre Todo Alimentacion S.A.De C.V

SobreTodoAlimentacionS.a.DeC.v

3773

usd

roag

Sobre Todo Alimentacion S.A.De C.V

SobreTodoAlimentacionS.a.DeC.v

3773

usd

CY2021Q3

roag

Turasu Spr De Rl

TurasuSprDeRl

18706

usd

roag

Turasu Spr De Rl

TurasuSprDeRl

18706

usd

CY2021Q3

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

61985

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

61985

usd

CY2021Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-187523

usd

CY2020Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-308919

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-1168829

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

-3242490

usd

CY2021Q3

roag

Net Income Loss Per Share Applicable To Common Stockholders Basic

NetIncomeLossPerShareApplicableToCommonStockholdersBasic

-0.00

CY2020Q3

roag

Net Income Loss Per Share Applicable To Common Stockholders Basic

NetIncomeLossPerShareApplicableToCommonStockholdersBasic

-0.00

roag

Net Income Loss Per Share Applicable To Common Stockholders Basic

NetIncomeLossPerShareApplicableToCommonStockholdersBasic

-0.01

roag

Net Income Loss Per Share Applicable To Common Stockholders Basic

NetIncomeLossPerShareApplicableToCommonStockholdersBasic

-0.03

CY2021Q3

roag

Net Income Loss Per Share Applicable To Common Stockholders Diluted

NetIncomeLossPerShareApplicableToCommonStockholdersDiluted

-0.00

CY2020Q3

roag

Net Income Loss Per Share Applicable To Common Stockholders Diluted

NetIncomeLossPerShareApplicableToCommonStockholdersDiluted

-0.00

roag

Net Income Loss Per Share Applicable To Common Stockholders Diluted

NetIncomeLossPerShareApplicableToCommonStockholdersDiluted

-0.01

roag

Net Income Loss Per Share Applicable To Common Stockholders Diluted

NetIncomeLossPerShareApplicableToCommonStockholdersDiluted

-0.03

CY2021Q3

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

115739401

shares

CY2020Q3

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

97081861

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

115739401

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

97081861

shares

CY2021Q3

roag

Weighted Average Number Of Common Shares Outstanding Diluted

WeightedAverageNumberOfCommonSharesOutstandingDiluted

115739401

shares

CY2020Q3

roag

Weighted Average Number Of Common Shares Outstanding Diluted

WeightedAverageNumberOfCommonSharesOutstandingDiluted

97081861

shares

roag

Weighted Average Number Of Common Shares Outstanding Diluted

WeightedAverageNumberOfCommonSharesOutstandingDiluted

115739401

shares

roag

Weighted Average Number Of Common Shares Outstanding Diluted

WeightedAverageNumberOfCommonSharesOutstandingDiluted

97081861

shares

CY2020Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-5140453

usd

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

-2916070

usd

CY2020Q2

roag

Issuance Of Series E Preferred Stock To Officer As Compensation

IssuanceOfSeriesEPreferredStockToOfficerAsCompensation

17500

usd

CY2020Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-8039023

usd

CY2020Q3

roag

Issuance Of Series E Preferred Stock In Exchange For Fees And Services Rendered

IssuanceOfSeriesEPreferredStockInExchangeForFeesAndServicesRendered

40000

usd

CY2020Q3

us-gaap

Net Income Loss

NetIncomeLoss

-308919

usd

CY2020Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-8307941

usd

CY2020Q4

us-gaap

Net Income Loss

NetIncomeLoss

2676269

usd

CY2020Q4

roag

Issuance Of Series E Preferred Stock To Officer As Compensation

IssuanceOfSeriesEPreferredStockToOfficerAsCompensation

48328

usd

CY2020Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-5583344

usd

CY2021Q1

roag

Issuance Of Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings Value

IssuanceOfSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue

40000

usd

CY2021Q1

roag

Issuance Of Series E Preferred And Common Stock As Compensation To Employees Officers Andor Director

IssuanceOfSeriesEPreferredAndCommonStockAsCompensationToEmployeesOfficersAndorDirector

90000

usd

CY2021Q1

roag

Issuance Of Series E Preferred And Common Stock As Compensation To Employees Officers Andor Directors

IssuanceOfSeriesEPreferredAndCommonStockAsCompensationToEmployeesOfficersAndorDirectors

225000

usd

CY2021Q1

roag

Issuance Of Series E Preferred Stock In Exchange For Fees And Services Rendered

IssuanceOfSeriesEPreferredStockInExchangeForFeesAndServicesRendered

125000

usd

CY2021Q1

roag

Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value

IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue

100000

usd

CY2021Q1

roag

Conversion Of Convertible Notes Payabe And Accrued Interest Into Common Stock

ConversionOfConvertibleNotesPayabeAndAccruedInterestIntoCommonStock

11001

usd

CY2021Q1

us-gaap

Net Income Loss

NetIncomeLoss

-530248

usd

CY2021Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-5522591

usd

CY2021Q2

us-gaap

Net Income Loss

NetIncomeLoss

-461239

usd

CY2021Q2

roag

Human Brands International Inc Merge

HumanBrandsInternationalIncMerge

22653872

usd

CY2021Q2

roag

Not Issued Series E Preferred Stock In Connection With Sales Made Under Private Or Public Offerings

NotIssuedSeriesEPreferredStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferings

20000

usd

CY2021Q2

roag

Issuance Of Common Stock In Connection With Sales Made Under Private Or Public Offerings Value

IssuanceOfCommonStockInConnectionWithSalesMadeUnderPrivateOrPublicOfferingsValue

99380

usd

CY2021Q2

roag

Conversion Of Convertible Debentures And Accrued Interest Into Common Stock

ConversionOfConvertibleDebenturesAndAccruedInterestIntoCommonStock

680449

usd

CY2021Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

17469871

usd

CY2021Q3

us-gaap

Net Income Loss

NetIncomeLoss

-249507

usd

CY2021Q3

roag

Adjustment

2

usd

CY2021Q3

roag

Third Parties Investment Closing Pending

ThirdPartiesInvestmentClosingPending

201667

usd

CY2021Q3

roag

Conversion Of Convertible Notes Payabe And Accrued Interest Into Common Stock

ConversionOfConvertibleNotesPayabeAndAccruedInterestIntoCommonStock

201086

usd

CY2021Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

17623120

usd

roag

Net Loss

NetLoss

1230814

usd

roag

Net Loss

NetLoss

566221

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

16870

usd

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

35000

usd

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

49450

usd

roag

Common Stock Issued In Exchange For Fees And Services

CommonStockIssuedInExchangeForFeesAndServices

40000

usd

roag

Preferred Stock Issued As Compensation To Employees Officers Andor Directors

PreferredStockIssuedAsCompensationToEmployeesOfficersAndorDirectors

-90000

usd

us-gaap

Increase Decrease In Prepaid Deferred Expense And Other Assets

IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

145000

usd

roag

Preferred Stock Issued In Exchange For Fees And Services

PreferredStockIssuedInExchangeForFeesAndServices

-129961

usd

us-gaap

Gain Loss On Sale Of Derivatives

GainLossOnSaleOfDerivatives

-635634

usd

us-gaap

Gain Loss On Sale Of Derivatives

GainLossOnSaleOfDerivatives

104386

usd

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

258600

usd

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

-25745

usd

us-gaap

Increase Decrease In Other Current Assets

IncreaseDecreaseInOtherCurrentAssets

-234

usd

roag

Assets Impairement

AssetsImpairement

14418

usd

us-gaap

Increase Decrease In Accounts Payable

IncreaseDecreaseInAccountsPayable

-520382

usd

us-gaap

Increase Decrease In Accrued Liabilities

IncreaseDecreaseInAccruedLiabilities

1718718

usd

us-gaap

Increase Decrease In Accrued Liabilities

IncreaseDecreaseInAccruedLiabilities

345438

usd

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

114514

usd

roag

Increase Decrease In Related Party Loans

IncreaseDecreaseInRelatedPartyLoans

4350

usd

us-gaap

Increase Decrease In Employee Related Liabilities

IncreaseDecreaseInEmployeeRelatedLiabilities

190629

usd

us-gaap

Increase Decrease In Other Current Liabilities

IncreaseDecreaseInOtherCurrentLiabilities

-110

usd

roag

Increase Decrease In Contingencias And Commitments

IncreaseDecreaseInContingenciasAndCommitments

201667

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

1013523

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

-101408

usd

roag

Cash Received From Merger Transaction

CashReceivedFromMergerTransaction

179815

usd

us-gaap

Proceeds From Sale Of Intangible Assets

ProceedsFromSaleOfIntangibleAssets

14418

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

194233

usd

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

227713

usd

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

20000

usd

us-gaap

Proceeds From Sale Of Loans Receivable

ProceedsFromSaleOfLoansReceivable

50000

usd

us-gaap

Proceeds From Issuance Of Preferred Stock And Preference Stock

ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

60000

usd

us-gaap

Proceeds From Notes Payable

ProceedsFromNotesPayable

50787

usd

roag

Proceeds From Short Term Loans

ProceedsFromShortTermLoans

-1364501

usd

roag

Related Party Loan

RelatedPartyLoan

-1550

usd

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

12500

usd

roag

Proceeds From Promissory Note

ProceedsFromPromissoryNote

-0

usd

roag

Proceeds From Promissory Note

ProceedsFromPromissoryNote

81500

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1163526

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

101500

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

44231

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

92

usd

CY2020Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

111

usd

CY2019Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

19

usd

CY2021Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

44342

usd

CY2020Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

111

usd

roag

Common Stock Issued To Reduce Convertible Promissory Notes Payable

CommonStockIssuedToReduceConvertiblePromissoryNotesPayable

892536

usd

roag

Series E Preferred Stock Issued In Lieu Of Cash For Accrued Officer Compensation

SeriesEPreferredStockIssuedInLieuOfCashForAccruedOfficerCompensation

225000

usd

roag

Common Stock Issued In Connection With Acquisition Of Business

CommonStockIssuedInConnectionWithAcquisitionOfBusiness

8467377

usd

roag

Preferred Stock Issued In Connection With Acquisition Of Business

PreferredStockIssuedInConnectionWithAcquisitionOfBusiness

10777500

usd

roag

Nature Of Business

NatureOfBusiness

Nature of Business Rogue One, Inc. (“Rogue One” or the “Company”) is a consumer products and marketing company focused on the high-margin, multi-trillion-dollar alcoholic beverages sector. On June 27, 2017, Creative Edge Nutrition, a Nevada corporation ("CEN") and Rogue One executed an asset purchase agreement whereby the Company purchased the assets and liabilities of CEN's subsidiary, Giddy Up Energy Products, Inc. ("Giddy"). As consideration, the Company agreed to exchange 47,197,601 shares of its common stock. On January 24, 2018, the Company completed the distribution of its common shares to the CEN shareholders to consummate the acquisition of Giddy. On December 7, 2020, the Company and Giddy entered into a Settlement Agreement, Waiver and Release of Claims whereby each party warranted and represented that they sought to fully and mutually rescind the purchase agreement dated June 27, 2017 and, in so doing, for Giddy to acquire the assets previously sold and, at the same time, for each of the parties to waive and release all claims, both known and unknown, and to indemnify and hold all other parties harmless. In addition, the parties agreed to enter into an exclusive licensing agreement for the Giddy Up brand in the category of alcoholic beverages. On September 23, 2020, the Company entered into a Merger Agreement and Plan of Reorganization with Human Brands International, Inc., a private corporation organized pursuant to the laws of the State of Nevada (“Human Brands”), pursuant to which, at the effective time, Human Brands shareholders will exchange 100% of the equity in Human Brands in exchange for a majority controlling interest in the Company. On June 30, 2021, the Acquisition Agreement was made effective pending certain closing conditions. Under the terms of the Acquisition Agreement, the Company agreed to issue an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Stock issued during period for acquisitions">45 shares of its Series D preferred stock and an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock issued during period for acquisitions">176,771,962 shares of its common stock to acquire all of the outstanding capital stock of Human Brands. Human Brands operating divisions currently own and manage over 250,000 agave plants, several premium spirit brands, and hold exclusive import and export rights for a variety of spirit brands. Its core foundation is built upon its bulk tequila production operations. Human Brands currently has supply contracts with well- known tequila brands, celebrities, and athletes. On April 7, 2021, the Company effected a 1-for-100 reverse split which as preceded by a filing of an amendment to its Articles of Incorporation that the Company completed with the Nevada Secretary of State on February 13, 2021. On April 7, 2021, the Company also amended its Articles of Incorporation to change its name to Rogue One, Inc. On June 30, 2021, the Company entered into that certain Merger Agreement and Plan of Reorganization (the “Acquisition Agreement”) with each of the stockholders of Human Brands International, Inc., a Nevada corporation (the “Acquired Company” or “Human Brands”), finishing the merger initiated on September 23, 2020. Under the terms of the Acquisition Agreement, the Company agreed to issue an aggregate of forty-seven (47) shares of Series D Preferred Stock (par value $0.001) (the “Preferred Shares”) and an aggregate of One Hundred Seventy-Six Million Seven Hundred Seventy-One Thousand Nine Hundred Sixty-Two (176,771,962) shares of Common Stock (par value $0.001) (the “Common Shares”) to acquire all of the outstanding capital stock of the Acquired Company. The Acquisition Agreement was the product of several months of meetings and due diligence conducted by the Company’s officers and directors that resulted in successful negotiations with the officers and directors of the Acquired Company and the stockholders of the Acquired Company. The Company did not employ or utilize the services of any investment banker, advisor, or other third party in connection with the Acquisition Agreement, the transactions underlying the Acquisition Agreement or both of them. As a result, the Company did not incur or pay any fees to any investment banker, advisor, or other third party but may ignored critically important aspects of the business conducted by the Acquired Company that we may later discover with materially adverse consequences to the Company’s financial condition for an indefinite period of time. All of the Preferred Shares and all of the Common Shares that were issued in accordance with the Acquisition Agreement are “unregistered securities” in that they were issued pursuant to claims of exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 506(b) promulgated by the Securities and Exchange Commission thereunder as well as certain claims to the qualification requirements under state securities laws in the states wherein the holders of all of the outstanding capital stock of the Acquired Company. Moreover, all of the Preferred Shares and all of the Common Shares that were issued pursuant to the Acquisition Agreement were issued with a restricted securities legend and only then after we received certain additional written assurances from the stockholders of the Acquired Company. Human Brands was founded in late 2014 with a plan to capitalize in perceived growth prospects in the consumer alcoholic products industry. In recent years Human Brands has focused on the tequila products segment within that industry as management believes that the tequila products segment may offer stronger sales growth opportunities relative to other consumer alcoholic segments. The management of Human Brands follows a “ground to glass” strategy that, in practical terms, means that management attempts to control marketing, sales, and assets throughout the selection of raw materials (the agave plants) and the operation of the manufacturing process. The strategy also involves selection and constant management of the marketing channels, advertising programs, and target marketing strategies. Human Brands has had to confront ever-rising costs for raw materials as agave prices have increased by about 694% since 2016. Currently Human Brands has approximately 400,000 agave plants and has adopted a strategy to grow more agave plants to ensure that the company has a stable supply of raw materials and at price levels that may serve to insulate the company from excessive price increases in the market. The company has adopted a two-part strategy: (a) sell agave plants to generate revenues; and (b) at the same time, use agave produced by the company’s own agave plants as raw material for the company’s tequila products. The Company believes that, if circumstances allow, this strategy may serve to insulate the company from some of the excessive cost pressures in the raw agave market. Cautionary Statement on Forward-Looking Statements All statements, other than statements of current or historical fact, contained in this filing are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Rogue One, Inc., and its subsidiaries (Rogue, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of our recently completed acquisition of Human Brands International, Inc., and its subsidiaries (the Human Brands Acquisition), and future acquisitions, investments and the adequacy of our available cash resources. These statements may be found in the various sections of this filing, such as Part I, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations." and Part II, These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this Notes are based on information available to us on the date of this filing. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this filing, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The impact of COVID-19 on global markets, economic conditions, the healthcare industry and our results of operations and the response by governments and other third parties.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk that regulatory or other approvals required for the HBI Acquisition may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management's time and our resources or otherwise have an adverse effect on us.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The possibility that certain conditions to the consummation of the HBI Acquisition will not be satisfied or completed on a timely basis and accordingly the HBI Acquisition may not be consummated on a timely basis or at all.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Uncertainty as to the expected financial performance of the combined company following completion of the HBI Acquisition.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The possibility that the expected synergies and value creation from the HBI Acquisition will not be realized or will not be realized within the applicable expected time periods.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The exertion of management's time and our resources, and other expenses incurred, and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third-party consents or approvals for the HBI Acquisition.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk that unexpected costs will be incurred in connection with the completion and/or integration of the HBI Acquisition or that the integration of its subsidiaries will be more difficult or time consuming than expected.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk that potential litigation in connection with the HBI Acquisition may affect the timing or occurrence of the HBI Acquisition or result in significant costs of defense, indemnification and liability.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">A downgrade of the credit rating of our indebtedness, which could give rise to an obligation to redeem existing indebtedness.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The inability to retain key personnel.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Disruption from the announcement, pendency and/or completion and/or integration of the HBI Acquisition or the integration of the subsidiaries, or similar risks from other acquisitions we may announce or complete from time to time, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves,</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Competition.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Membership and revenue declines or unexpected trends.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Changes in the beverage industry practices, new technologies, and advances in processing and distillation methods.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Increased feedstock costs.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Changes in economic, political or market conditions.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Changes in federal or state laws or regulations, including changes with respect to income tax reform or government beverage industry programs as well as changes with and any regulations enacted thereunder that may result from changing political conditions, the new administration or judicial actions.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Our ability to adequately price products.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Tax matters.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Disasters or major epidemics.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Changes in expected contract start dates.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Provider, state, federal, foreign, and other contract changes and timing of regulatory approval of contracts.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The difficulty of predicting the timing or outcome of pending or future legal and regulatory proceedings or government investigations.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Challenges to our contract awards.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Cyber-attacks or other privacy or data security incidents.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The possibility that the expected synergies and value creation from acquired businesses, including businesses we may acquire in the future, will not be realized, or will not be realized within the expected time period.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 2.5pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">The exertion of management's time and our resources, and other expenses incurred, and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third-party consents or approvals for acquisitions.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-right: 14.2pt; padding-bottom: 6pt; text-align: justify; line-height: 115%">Disruption caused by significant completed and pending acquisitions making it more difficult to maintain business and operational relationships.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">Changes in expected closing dates, estimated purchase price and accretion for acquisitions.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk that acquired businesses will not be integrated successfully.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">Restrictions and limitations in connection with our indebtedness.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">Availability of debt and equity financing, on terms that are favorable to us.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">Inflation; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 6pt; line-height: 115%">•</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">Foreign currency fluctuations.</td></tr> </table> This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition and results of operations, in our filings with the Securities and Exchange Commission (SEC), including quarterly reports on Form 10-Q and current reports on Form 8-K. Item 1A. "Risk Factors" of Part I of this Notes contains a further discussion of these and other important factors that could cause actual results to differ from expectations. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future cultivation, harvesting, distillation and selling, general and administrative costs.

CY2021Q2

us-gaap

Stockholders Equity Reverse Stock Split

StockholdersEquityReverseStockSplit

1-for-100

CY2020Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

0

usd

CY2021Q3

us-gaap

Operating Loss Carryforwards

OperatingLossCarryforwards

17400000

usd

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.21

pure

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

CY2021Q3

us-gaap

Cash Fdic Insured Amount

CashFDICInsuredAmount

250000

usd

roag

Net Income Loss Applicable To Common Shareholders

NetIncomeLossApplicableToCommonShareholders

-1230814

usd

roag

Net Income Loss Applicable To Common Shareholders

NetIncomeLossApplicableToCommonShareholders

-3242490

usd

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

115739401

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

97081861

shares

roag

Convertible Preferred Stock

ConvertiblePreferredStock

250000000

shares

roag

Convertible Preferred Stock

ConvertiblePreferredStock

100000000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

365739401

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

197081861

shares

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.01

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

-0.03

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.00

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

-0.02

roag

Net Loss

NetLoss

1230814

usd

CY2021Q3

roag

Working Capital Deficit

WorkingCapitalDeficit

6269364

usd

CY2021Q3

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

15900941

usd

CY2021Q3

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

44342

usd

CY2020Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

111

usd

CY2021Q3

us-gaap

Accounts Receivable Net

AccountsReceivableNet

826297

usd

CY2020Q4

us-gaap

Accounts Receivable Net

AccountsReceivableNet

0

usd

CY2021Q3

us-gaap

Minority Interest

MinorityInterest

3408995

usd

CY2021Q3

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

298079

usd

CY2021Q3

roag

Account Receivable130

AccountReceivable130

174568

usd

CY2021Q3

roag

Account Receivable3160

AccountReceivable3160

54731

usd

CY2021Q3

roag

Account Receivable6190

AccountReceivable6190

66657

usd

CY2021Q3

roag

Account Receivable91 And Over

AccountReceivable91AndOver

232262

usd

CY2021Q3

us-gaap

Accounts Receivable Net

AccountsReceivableNet

826297

usd

CY2021Q3

us-gaap

Inventory Finished Goods

InventoryFinishedGoods

13253

usd

CY2021Q3

us-gaap

Inventory Raw Materials And Supplies

InventoryRawMaterialsAndSupplies

94171

usd

CY2021Q3

roag

Inventory Biological Assets

InventoryBiologicalAssets

6889130

usd

CY2021Q3

us-gaap

Inventory Net

InventoryNet

6996553

usd

roag

Total Equity Value

TotalEquityValue

7432862

usd

roag

Market Value Equity

MarketValueEquity

11033306

usd

CY2021Q3

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

315300

usd

us-gaap

Depreciation

16870

usd

CY2021Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

331846

usd

CY2021Q3

us-gaap

Depreciation

16870

usd

CY2021Q3

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

16870

usd

CY2021Q3

roag

Net Value

NetValue

314976

usd

CY2021Q3

roag

Prepayments

120000

usd

CY2021Q3

us-gaap

Security Deposit

SecurityDeposit

2195

usd

CY2021Q3

roag

Security Deposits Rent

SecurityDepositsRent

3903

usd

CY2021Q3

roag

Janon Costley

JanonCostley

1250

usd

CY2021Q3

roag

Creditable Paid Iva

CreditablePaidIva

129

usd

CY2021Q3

roag

Creditable Paid Ieps

CreditablePaidIeps

151

usd

CY2021Q3

roag

Iva Pending

IvaPending

42

usd

CY2021Q3

roag

Ieps Pending

IepsPending

410

usd

CY2021Q3

us-gaap

Other Assets Current

OtherAssetsCurrent

128080

usd

CY2021Q3

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

0

usd

CY2020Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

0

usd

CY2021Q3

us-gaap

Goodwill

10804239

usd

CY2021Q3

us-gaap

Derivative Liabilities Current

DerivativeLiabilitiesCurrent

2934454

usd

CY2020Q4

us-gaap

Derivative Liabilities Current

DerivativeLiabilitiesCurrent

2298820

usd

roag

Schedule Of Fair Value Of Assumptions Used

ScheduleOfFairValueOfAssumptionsUsed

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssumptionsUsed_zBS5sWJ2Bza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONVERTIBLE NOTES PAYABLE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Schedule of fair value of assumptions used</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center">December 31,</td><td style="text-align: center"> </td> <td colspan="3" style="text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Expected dividend yield (1)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Risk-free interest rate (2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_fKDIp_zmusxBLSsd46" title="Risk-free interest rate">0.05 – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_fKDIp_z5vLUyuMz4yg" title="Risk-free interest rate">0.07%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_fKDIp_zDqbKuEGzXD2" title="Risk-free interest rate">0.09 – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_fKDIp_z77Pn2TQ6U2c" title="Risk-free interest rate">0.17%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Expected volatility (3)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_fKDMp_zGnIqITwdyVk" title="Expected volatility">253.5 – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_fKDMp_zDq3WE3uHEc9" title="Expected volatility">415.6%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_fKDMp_z3kyoC4pFRvb" title="Expected volatility">199.52 – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_fKDMp_zgvBGEj2OiXd" title="Expected volatility">582.91%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zzbwfdHs0dl7" title="Expected life (in years)">0.5 – <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_zXFW0IfNEnh" title="Expected life (in years)">1.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zAL1wljeWhYe" title="Expected life (in years)">0.5 – <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zXb4H2jq7G1h" title="Expected life (in years)">1.0</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"> </td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%">(1)</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">The Company has no history or expectation of paying cash dividends on its common stock.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"> </td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%">(2)</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the promissory notes in effect at the time of issuance.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8px"> </td> <td style="width: 38px; padding-bottom: 6pt; line-height: 115%">(3)</td> <td style="padding-bottom: 6pt; text-align: justify; line-height: 115%">The volatility of the Company’s common stock is based on trading activity for the previous contractual term ended at each promissory note issuance date.</td></tr> </table>

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0000

pure

CY2020

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.0000

pure

roag

Revenues From Related Parties

RevenuesFromRelatedParties

1198434

usd

CY2020

roag

Revenues From Related Parties

RevenuesFromRelatedParties

1931303

usd

CY2019

roag

Revenues From Related Parties

RevenuesFromRelatedParties

110244

usd

CY2021Q3

roag

Principal Value Of Convertible Notes

PrincipalValueOfConvertibleNotes

1316584

usd

CY2020Q4

roag

Principal Value Of Convertible Notes

PrincipalValueOfConvertibleNotes

1595553

usd

CY2020Q4

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

35750

usd

CY2021Q3

roag

Other Convertibles

OtherConvertibles

169364

usd

CY2021Q3

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1485948

usd

CY2020Q4

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1559803

usd

CY2020Q4

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1559803

usd

us-gaap

Amortization Of Financing Costs And Discounts

AmortizationOfFinancingCostsAndDiscounts

33750

usd

roag

Conversion Of Principal Amounts Outstanding Into Common Stock Of Company

ConversionOfPrincipalAmountsOutstandingIntoCommonStockOfCompany

-276969

usd

CY2021Q3

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1485948

usd

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

-1402488

usd

us-gaap

Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate

IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

-3242490

usd

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

-1402488

usd

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

-3242490

usd

us-gaap

Valuation Allowances And Reserves Deductions

ValuationAllowancesAndReservesDeductions

1402488

usd

us-gaap

Valuation Allowances And Reserves Deductions

ValuationAllowancesAndReservesDeductions

3242490

usd

CY2021Q3

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

5072195

usd

CY2020Q4

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

3080727

usd

CY2021Q3

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

5072195

usd

CY2020Q4

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

3080727

usd

CY2020Q4

us-gaap

Embedded Derivative Fair Value Of Embedded Derivative Liability

EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability

2298820

usd

CY2020Q4

us-gaap

Derivative Liabilities

DerivativeLiabilities

2298820

usd

roag

Schedule Of Changes In Derivative Liabilities At Fair Value

ScheduleOfChangesInDerivativeLiabilitiesAtFairValue

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfChangesInDerivativeLiabilitiesAtFairValue_zAvbYIvBRdfk" style="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"> <tr> <td colspan="3" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Schedule of Changes in Derivative Liabilities at Fair Value</td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td colspan="2" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">Beginning balance, January 1, 2021</td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pp0p0_c20210101__20210930_zijchLw3WFE1" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Beginning balance">- </td></tr> <tr style="background-color: white"> <td colspan="4" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Change in fair value of embedded conversion features of convertible promissory notes included in earnings</td> <td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_c20210101__20210930_pp0p0" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Change in fair value of embedded conversion features of convertible promissory notes and warrants included in earnings">- </td></tr> <tr style="background-color: #CCEEFF"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"> </td></tr> <tr style="background-color: white"> <td colspan="4" rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">Embedded conversion option liability recorded in connection with the issuance of convertible promissory notes</td> <td id="xdx_982_ecustom--RecordNonCashDerivativeLiabilityOnNotes_c20210101__20210930_pp0p0" style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Embedded conversion option & warrant liability recorded in connection with the issuance of convertible promissory notes">- </td></tr> <tr style="background-color: #CCEEFF"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; width: 66%; padding-right: 5.4pt; padding-left: 5.4pt">Ending balance, September 30, 2021</td> <td style="white-space: nowrap; vertical-align: bottom; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 1%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt"> </td> <td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pp0p0_c20210101__20210930_zx9FVr8gBo97" style="border-top: black 1pt solid; border-bottom: black 2.25pt double; white-space: nowrap; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right" title="Ending balance">- </td></tr> <tr style="background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

Concept	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.189M	$110.00
YoY Change	5849428.57%
Cash & Equivalents	$44.34K	$110.00
Short-Term Investments	$8.145M
Other Short-Term Assets	$128.1K
YoY Change
Inventory	$6.997M
Prepaid Expenses
Receivables	$298.1K
Other Receivables	$0.00
Total Short-Term Assets	$16.14M	$110.00
YoY Change	11528667.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$315.3K	$0.00
YoY Change
Goodwill	$10.80M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$11.51M	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$16.14M	$110.00
Total Long-Term Assets	$11.51M	$0.00
Total Assets	$27.65M	$110.00
YoY Change	19749901.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.785M	$165.5K
YoY Change	978.95%
Accrued Expenses	$1.090M	$1.555M
YoY Change	-24.34%
Deferred Revenue
YoY Change
Short-Term Debt	$2.383M	$1.560M
YoY Change	52.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.871M	$5.583M
YoY Change	18.81%
LONG-TERM LIABILITIES
Long-Term Debt	$156.0K	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.871M	$5.583M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$10.03M	$5.583M
YoY Change	20.69%
SHAREHOLDERS EQUITY
Retained Earnings	$15.90M
YoY Change
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.21M	-$5.583M
YoY Change
Total Liabilities & Shareholders Equity	$27.65M	$110.00
YoY Change	19749901.43%

Name	View Source	Status
0001903596-23-000224-index-headers.html	Edgar Link	pending
0001903596-23-000224-index.html	Edgar Link	pending
0001903596-23-000224.txt	Edgar Link	pending
0001903596-23-000224-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_009.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
roag-20210930.xsd	Edgar Link	pending
roag_10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
roag-20210930_cal.xml	Edgar Link	unprocessable
roag-20210930_lab.xml	Edgar Link	unprocessable
roag-20210930_def.xml	Edgar Link	unprocessable
roag_10q_htm.xml	Edgar Link	completed
roag-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Rogue One, Inc.

2023 Q1 Form 10-Q Financial Statement

#000190359623000224 Filed on March 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission